Germline genetic variants in men with prostate cancer and one or more additional cancers
Open Access
- 28 June 2017
- Vol. 123 (20), 3925-3932
- https://doi.org/10.1002/cncr.30817
Abstract
BACKGROUND Prostate cancer has a significant heritable component, and rare deleterious germline variants in certain genes can increase the risk of the disease. The aim of the current study was to describe the prevalence of pathogenic germline variants in cancer‐predisposing genes in men with prostate cancer and at least 1 additional primary cancer. METHODS Using a multigene panel, the authors sequenced germline DNA from 102 men with prostate cancer and at least 1 additional primary cancer who also met ≥1 of the following criteria: 1) age ≤55 years at the time of diagnosis of the first malignancy; 2) rare tumor type or atypical presentation of a common tumor; and/or 3) ≥3 primary malignancies. Cancer family history and clinicopathologic data were independently reviewed by a clinical genetic counselor to determine whether the patient met established criteria for testing for a hereditary cancer syndrome. RESULTS Sequencing identified approximately 3500 variants. Nine protein‐truncating deleterious mutations were found across 6 genes, including BRCA2, ataxia telangiectasia mutated (ATM), mutL homolog 1 (MLH1), BRCA1 interacting protein C‐terminal helicase 1 (BRIP1), partner and localizer of BRCA2 (PALB2), and fibroblast growth factor receptor 3 (FGFR3). Likely pathogenic missense variants were identified in checkpoint kinase 2 (CHEK2) and homeobox protein Hox‐B13 (HOXB13). In total, 11 of 102 patients (10.8%) were found to have pathogenic or likely pathogenic mutations in cancer‐predisposing genes. The majority of these men (64%) did not meet current clinical criteria for germline testing. CONCLUSIONS Men with prostate cancer and at least 1 additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer‐predisposing gene that may impact cancer prognosis and treatment, but the majority do not meet current criteria for clinical genetic testing. Cancer 2017;123:3925‐32. © 2017 American Cancer Society.Keywords
Funding Information
- University of Michigan Prostate Cancer Specialized Program of Research Excellence (SPORE) (P50 CA186786)
- University of Michigan Comprehensive Cancer Center Sequencing Core
This publication has 32 references indexed in Scilit:
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at DeathEuropean Urology, 2016
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerThe New England Journal of Medicine, 2016
- Using ClinVar as a Resource to Support Variant InterpretationCurrent Protocols in Human Genetics, 2016
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAJAMA Oncology, 2016
- Germline Mutations in Predisposition Genes in Pediatric CancerThe New England Journal of Medicine, 2015
- High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal CancerJournal of Clinical Oncology, 2015
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerEuropean Urology, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- A clinical and genetic analysis of multiple primary cancer referrals to genetics servicesEuropean Journal of Human Genetics, 2014
- Clinical retrospective analysis of cases with multiple primary malignant neoplasmsEvolution, 2014